Table q1_q4_2023_prescription_drug_wac

Table: q1_q4_2023_prescription_drug_wac_increases , manufacturer_name like P*

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	drug_category	drug_category_source	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000101	Par Pharmaceutical	09/30/2023	42023010501	BREVITAL SODIUM METHOHEXITAL SODIUM INJECTABLE 500MG/VIAL	Brand	FDA	07/10/2023	6.44	92.36	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 10/24/2023, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000101	Par Pharmaceutical	09/30/2023	42023011925	TIGAN TRIMETHOBENZAMIDE HYDROCHLORIDE INJECTABLE 100MG/ML, 25vl	Brand	FDA	07/10/2023	87.57	1255.18	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 10/24/2023, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000053	Paratek Pharmaceuticals, Inc.	09/30/2023	71715000102	Nuzyra 100mg Vial 10 Vials	Brand	FDA	07/01/2023	123.59	4243.06	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000053	Paratek Pharmaceuticals, Inc.	09/30/2023	71715000227	Nuzyra 150mg Oral Tablet 30 ct/ Carton	Brand	FDA	07/01/2023	223.25	7664.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000053	Paratek Pharmaceuticals, Inc.	09/30/2023	71715000221	Nuzyra 150mg Oral Tablet 6 ct/ Carton	Brand	FDA	07/01/2023	44.65	1532.94	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000053	Paratek Pharmaceuticals, Inc.	03/31/2023	71715000227	Nuzyra Oral Tablet 150 MG 30 pack	Brand	FDA	01/01/2023	216.75	7441.59	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000053	Paratek Pharmaceuticals, Inc.	03/31/2023	71715000221	Nuzyra Oral Tablet 150 MG 6 pack	Brand	FDA	01/01/2023	43.34	1488.29	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000006	Pfizer	09/30/2023	00409005101	ADD-Vantage, ADDapter Connector, 1	Brand	Medispan	07/01/2023	3.67	40.36	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00008042303	Antivenin (micrurus fulvius equine origin), 10mL, 1 VIAL	Brand	FDA	01/01/2023	313.55	6584.74	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00008042303	Antivenin (micrurus fulvius equine origin), 10mL, VIAL (ML), 1	Brand	FDA	07/01/2023	329.24	6913.98	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00009722402	ATGAM (lymphocyte immune globulin,antithymocyte (equine)), 50 mg/mL, 5 AMPULS (ML)	Brand	FDA	01/01/2023	1431.45	15745.91	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009722402	ATGAM (lymphocyte immune globulin,antithymocyte (equine)), 50 mg/mL, Ampul(ML), 5	Brand	FDA	07/01/2023	1574.59	17320.50	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409963005	ATROPINE SULFATE (atropine sulfate), 0.05 mg/mL, SYRINGE (ML), 1	Brand	FDA	07/01/2023	18.52	203.75	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	60793060010	BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (600,000/600,000), 10 SYRINGES (ML)	Brand	FDA	01/01/2023	166.05	1826.58	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	60793060110	BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (600,000/600,000), SYRINGE (ML), 1	Brand	FDA	07/01/2023	182.66	2009.24	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	60793060010	BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (600,000/600,000), SYRINGE (ML), 1	Brand	FDA	07/01/2023	182.66	2009.24	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	60793060210	BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (900,000/300,000), 10 SYRINGES (ML)	Brand	FDA	01/01/2023	166.05	1826.58	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	60793060210	BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (900,000/300,000), SYRINGE (ML), 1	Brand	FDA	07/01/2023	182.66	2009.24	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	60793060110	BICILLIN C-R (penicillin G benzathine/penicillin Gprocaine), 1,200,000 unit/2 mL (600,000/600,000), 10 SYRINGES (ML)	Brand	FDA	01/01/2023	166.05	1826.58	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	60793070110	BICILLIN L-A (penicillin G benzathine), 1.2 million unit/2 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	208.31	2291.42	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	60793070110	BICILLIN L-A (penicillin G benzathine), 1.2 million unit/2 mL, SYRINGE (ML), 1	Brand	FDA	07/01/2023	229.14	2520.56	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	60793070210	BICILLIN L-A (penicillin G benzathine), 2.4 million unit/4 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	426.86	4695.50	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	60793070210	BICILLIN L-A (penicillin G benzathine), 2.4 million unit/4 mL, SYRINGE (ML), 1	Brand	FDA	07/01/2023	469.55	5165.05	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	60793070010	BICILLIN L-A (penicillin G benzathine), 600,000 unit/mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	120.28	1323.03	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	60793070010	BICILLIN L-A (penicillin G benzathine), 600,000 unit/mL, SYRINGE (ML), 1	Brand	FDA	07/01/2023	132.30	1455.33	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069013501	BOSULIF (bosutinib), 100 mg, 120 TABLETS	Brand	FDA	01/01/2023	1371.57	18733.27	04/13/2024	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069013501	BOSULIF (bosutinib), 100 mg, TABLET, 1	Brand	FDA	07/01/2023	749.33	19482.60	04/13/2024	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069019301	BOSULIF (bosutinib), 400 mg, 1x30 BT TABLETS	Brand	FDA	01/01/2023	1371.57	18733.27	04/13/2024	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069019301	BOSULIF (bosutinib), 400 mg, TABLET, 1	Brand	FDA	07/01/2023	749.33	19482.60	04/13/2024	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069013601	BOSULIF (bosutinib), 500 mg, 30 TABLETS	Brand	FDA	01/01/2023	1371.57	18733.27	04/13/2024	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069013601	BOSULIF (bosutinib), 500 mg, TABLET, 1	Brand	FDA	07/01/2023	749.33	19482.60	04/13/2024	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	70255002503	BRAFTOVI (encorafenib), 75 mg, 2X60 BTL CAPSULES	Brand	FDA	01/01/2023	1056.52	14430.23	08/27/2030	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	07/30/2019	Array BioPharma Inc.	1120000000	None	On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs.	11499.00	10977.00	2018	10977.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	70255002501	BRAFTOVI (encorafenib), 75 mg, 2X90 BTL CAPSULES	Brand	FDA	01/01/2023	1056.52	14430.23	08/27/2030	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	07/30/2019	Array BioPharma Inc.	1120000000	None	On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs.	11499.00	10977.00	2018	10977.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	70255002503	BRAFTOVI (encorafenib), 75 mg, CAPSULE, 120	Brand	FDA	07/01/2023	577.21	15007.44	08/27/2030	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	07/30/2019	Array BioPharma Inc.	1120000000	None	On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs. The acquisition price is $11,200,000,000. The system would not allow us to enter the full acquisition price.	11499.00	10977.00	2018	10977.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	70255002501	BRAFTOVI (encorafenib), 75 mg, CAPSULE, 180	Brand	FDA	07/01/2023	577.21	15007.44	08/27/2030	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	07/30/2019	Array BioPharma Inc.	1120000000	None	On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs. The acquisition price is $11,200,000,000. The system would not allow us to enter the full acquisition price.	11499.00	10977.00	2018	10977.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409162301	BUTORPHANOL TARTRATE (butorphanol tartrate), 1 mg/mL, 10 VIALs (ML)	Generic	FDA	01/01/2023	5.07	55.74	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409162601	BUTORPHANOL TARTRATE (butorphanol tartrate), 2 mg/mL, 10 VIALS	Generic	FDA	01/01/2023	6.20	68.17	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409162602	BUTORPHANOL TARTRATE (butorphanol tartrate), 2 mg/mL, 10 VIALS (ML)	Generic	FDA	01/01/2023	8.73	95.98	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409162301	Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 1 mg/mL (1 mg/mL) Single Dose Glass Fliptop Vial, 10	Generic	FDA	07/01/2023	5.57	61.31	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409162601	Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (2 mg/mL) Single Dose Glass Fliptop Vial, 10	Generic	FDA	07/01/2023	6.82	74.99	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409162602	Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (4 mg/2 mL) Single Dose Glass Fliptop Vial, 10	Generic	FDA	07/01/2023	9.60	105.58	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069600125	CEREBYX (fosphenytoin sodium), 100 mg PE/2 mL, 25 VIALS (ML)	Brand	FDA	01/01/2023	45.84	962.66	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069600121	CEREBYX (fosphenytoin sodium), 500 mg PE/10 mL, 10 VIALS (ML)	Brand	FDA	01/01/2023	55.01	1155.19	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409477723	CIPROFLOXACIN-D5W, 200 mg/100 mL, INTRAVENOUS SOLUTION (ML), 100	Generic	Medispan	07/01/2023	8.73	66.96	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409477702	CIPROFLOXACIN-D5W, 400 mg/200 mL, INTRAVENOUS SOLUTION (ML), 200	Generic	Medispan	07/01/2023	10.78	82.64	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409409201	COPPER CHLORIDE (cupric chloride), 0.4 mg/mL, 25 VIALS	Brand	FDA	01/01/2023	54.15	595.65	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409409201	COPPER CHLORIDE (cupric chloride), 0.4 mg/mL, VIAL (ML), 25	Brand	FDA	07/01/2023	59.57	655.22	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409337301	CORLOPAM (fenoldopam mesylate), 10 mg/mL, 1 VIAL (ML)	Brand	Medispan	01/01/2023	42.95	497.90	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409337302	CORLOPAM (fenoldopam mesylate), 20 mg/mL, 1 VIAL (ML)	Brand	Medispan	01/01/2023	85.90	995.81	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009379422	CORVERT (ibutilide fumarate), 0.1 mg/mL, VIAL (ML), 10	Brand	FDA	07/01/2023	26.14	548.85	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009379401	CORVERT (ibutilide fumarate), 1 mg/10 mL, VIAL (ML), 10	Brand	FDA	07/01/2023	26.14	548.85	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069153130	DAURISMO (glasdegib maleate), 100 mg, 1X30 BTL TABLETS	Brand	FDA	01/01/2023	1181.16	20867.27	01/30/2031	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069029860	DAURISMO (glasdegib maleate), 25 mg, 1X60 BTL TABLETS	Brand	FDA	01/01/2023	1181.16	20867.27	01/30/2031	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409118130	DEMEROL (meperidine HCl), 50 mg/mL, 1 VIAL (ML)	Brand	FDA	01/01/2023	8.53	93.85	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409136201	DEMEROL (meperidine HCl/PF), 25 mg/mL, 1X10 NEXJECT SYRINGE (ML)	Brand	FDA	01/01/2023	8.05	88.51	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409136201	DEMEROL (meperidine HCl/PF), 25 mg/mL, SYRINGE (ML), 10	Brand	FDA	07/01/2023	8.85	97.36	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409141801	DEMEROL (meperidine HCl/PF), 50 mg/mL, 1X10 NEXJECT SYRINGE (ML)	Brand	FDA	01/01/2023	8.92	98.15	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409117830	DEMEROL (meperidine HCl/PF), 50 mg/mL, CARTRIDGE (ML), 1	Brand	FDA	07/01/2023	6.87	75.54	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409141801	DEMEROL (meperidine HCl/PF), 50 mg/mL, SYRINGE (ML), 10	Brand	FDA	07/01/2023	9.82	107.97	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409118130	Demerol™ (meperidine hydrochloride) Injection - Controlled Substance - SCHEDULE II Rx, 50 mg/mL (1,500 mg/30 mL) Multiple Dose Glass Fliptop Vial, 1	Brand	FDA	07/01/2023	9.39	103.24	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00009027101	DEPO-ESTRADIOL (estradiol cypionate), 5 mg/mL, 1 VIAL (ML)	Generic	FDA	01/01/2023	14.01	154.10	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009027101	DEPO-ESTRADIOL (estradiol cypionate), 5 mg/mL, VIAL (ML), 1	Generic	FDA	07/01/2023	14.55	168.65	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409741903	Dextran (dextran) Injection Rx, 500 mL (10% LMD in 0.9% Sodium Chloride), Intravenous solution, 12	Generic	FDA	07/01/2023	39.85	438.38	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409741803	Dextran (dextran) Injection Rx, 500 mL (10% LMD in 5% Dextrose), Intravenous solution, 12	Generic	FDA	07/01/2023	38.72	425.87	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409741903	Dextran (dextran), LMD 10% WITH 0.9% SOD CHLORIDE (dextran 40 in 0.9 % sodium chloride), 10 % (100 mg/mL), 12 VIALS	Generic	FDA	01/01/2023	36.23	398.53	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409741803	Dextran (dextran), LMD 10% WITH 5% DEXTROSE (dextran 40 in dextrose 5 % in water), 10 %, 12 VIALS	Generic	FDA	01/01/2023	35.20	387.15	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409582001	DOPAMINE HCL (dopamine HCl), 200 mg/5 mL (40 mg/mL), 25 VIALS	Brand	FDA	01/01/2023	11.07	84.89	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409582001	DOPAMINE HCL (dopamine HCl), 200 mg/5 mL (40 mg/mL), VIAL (ML), 25	Brand	FDA	07/01/2023	4.24	89.13	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409493301	EPINEPHRINE (epinephrine), 0.1 mg/mL, 1X10 ABBJ SYRINGE (ML)	Brand	FDA	01/01/2023	6.34	69.72	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409493301	Epinephrine Injection Rx, 1mg/10mL (0.1 mg/mL) ABBOJECT Single-dose syringe, 10	Brand	FDA	07/01/2023	6.97	76.69	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409127632	FENTANYL CITRATE (fentanyl citrate), 100 mcg/2 mL (50 mcg/mL), CARTRIDGE (ML), 2	Generic	Medispan	07/01/2023	2.31	25.44	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409909311	FENTANYL CITRATE (fentanyl citrate), 100 mcg/2 mL, CARTRIDGE (ML), 2	Brand	FDA	07/01/2023	0.75	8.20	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409909332	FENTANYL CITRATE (fentanyl citrate), 50 mcg/mL, AMPUL (ML), 2	Brand	FDA	07/01/2023	1.62	17.85	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409909335	FENTANYL CITRATE (fentanyl citrate), 50 mcg/mL, AMPUL (ML), 5	Brand	FDA	07/01/2023	2.17	23.84	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409909428	FENTANYL CITRATE (fentanyl citrate), 50 mcg/mL, VIAL (ML), 10	Brand	FDA	07/01/2023	8.49	93.40	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409909422	FENTANYL CITRATE (fentanyl citrate), 50 mcg/mL, VIAL (ML), 2	Brand	FDA	07/01/2023	3.50	38.50	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409909431	FENTANYL CITRATE (fentanyl citrate), 50 mcg/mL, VIAL (ML), 20	Brand	FDA	07/01/2023	17.64	194.01	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409909425	FENTANYL CITRATE (fentanyl citrate), 50 mcg/mL, VIAL (ML), 5	Brand	FDA	07/01/2023	5.25	57.74	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409909461	FENTANYL CITRATE (fentanyl citrate), 50 mcg/mL, VIAL (ML), 50	Brand	FDA	07/01/2023	49.47	544.14	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069021702	FRAGMIN (dalteparin sodium,porcine), 10,000 unit/mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	99.81	1097.88	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069022002	FRAGMIN (dalteparin sodium,porcine), 12,500 unit/0.5 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	124.77	1372.45	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069022302	FRAGMIN (dalteparin sodium,porcine), 15,000 unit/0.6 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	149.71	1646.84	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069022802	FRAGMIN (dalteparin sodium,porcine), 18,000 unit/0.72 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	179.66	1976.21	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069019502	FRAGMIN (dalteparin sodium,porcine), 2,500 unit/0.2 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	30.76	338.35	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069023201	FRAGMIN (dalteparin sodium,porcine), 25,000 unit/mL, 1 VIAL (ML)	Brand	FDA	01/01/2023	85.79	943.68	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069019602	FRAGMIN (dalteparin sodium,porcine), 5,000 unit/0.2 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	49.90	548.94	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069020602	FRAGMIN (dalteparin sodium,porcine), 7,500 unit/0.3 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	74.86	823.50	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069021702	Fragmin® (dalteparin sodium) Injection Rx, 10,000 IU/1 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	Brand	FDA	07/01/2023	109.79	1207.67	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069022002	Fragmin® (dalteparin sodium) Injection Rx, 12,500 IU/0.5 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	Brand	FDA	07/01/2023	137.25	1509.70	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069022302	Fragmin® (dalteparin sodium) Injection Rx, 15,000 IU/0.6 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	Brand	FDA	07/01/2023	164.68	1811.52	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069022802	Fragmin® (dalteparin sodium) Injection Rx, 18,000 IU/0.72 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards test potency, 10	Brand	FDA	07/01/2023	197.62	2173.83	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069019502	Fragmin® (dalteparin sodium) Injection Rx, 2,500 IU/0.2 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	Brand	FDA	07/01/2023	33.84	372.19	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069019602	Fragmin® (dalteparin sodium) Injection Rx, 5,000 IU/0.2 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	Brand	FDA	07/01/2023	54.89	603.83	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069020602	Fragmin® (dalteparin sodium) Injection Rx, 7,500 IU/0.3 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	Brand	FDA	07/01/2023	82.35	905.85	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069023201	Fragmin® (dalteparin sodium) Injection Rx, 95,000 IU/3.8 mL Multidose Vial, 1	Brand	FDA	07/01/2023	94.37	1038.05	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409163910	FUROSEMIDE (furosemide), 10 mg/mL, 10 SYRINGES (ML)	Generic	Medispan	01/01/2023	22.43	246.76	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409120703	GENTAMICIN SULFATE (gentamicin sulfate), 40 mg/mL, 25 VIALS (ML)	Generic	FDA	01/01/2023	8.80	44.01	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409120703	Gentamicin Sulfate Injection Rx, 40 mg/mL (80 mg/2 mL) Single Dose Glass Fliptop Vial, 25	Generic	FDA	07/01/2023	11.00	55.01	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409765062	Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 100 Units/mL (25,000 Units/250 mL) Flexible Container, 24	Brand	FDA	07/01/2023	28.22	310.38	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409765062	Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 100 Units/mL (25,000 Units/250 mL) Flexible Container, 24 VIALS	Brand	FDA	01/01/2023	25.65	282.16	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409765162	Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 50 Units/mL (12,500 Units/250 mL) Flexible Container, 24	Generic	Medispan	07/01/2023	24.41	268.47	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409765162	Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 50 Units/mL (12,500 Units/250 mL) Flexible Container, 24 VIALS	Generic	Medispan	01/01/2023	22.19	244.06	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409131632	HEPARIN SODIUM (heparin sodium, porcine), 5000 unit/0.5 mL, CARTRIDGE (ML), 0.5	Generic	FDA	07/01/2023	18.79	206.71	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409140212	HEPARIN SODIUM (heparin sodium, porcine), 5000 unit/mL (1 mL), CARTRIDGE (ML), 1	Generic	FDA	07/01/2023	15.92	175.13	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409765103	HEPARIN SODIUM-0.45% NACL (heparin sodium,porcine in 0.45 % sodium chloride), 25,000 unit/500 mL (50 unit/mL), 24 VIALS	Generic	Medispan	01/01/2023	19.33	212.66	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409724803	HETASTARCH-0.9% NACL (hetastarch in 0.9 % sodium chloride), 6 %-0.9 %, 12 VIALS (ML)	Generic	FDA	01/01/2023	45.71	228.54	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409155554	HEXTEND LACTATED ELECTROLYTE (hetastarch/electrolyte solution,lactated), 500mL, Vial, 12	Brand	FDA	07/01/2023	95.07	1045.78	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409155554	HEXTEND LACTATED ELECTROLYTE (hetastarch/electrolyte solution,lactated), 6 %, 12 VIALS (ML)	Brand	FDA	01/01/2023	86.43	950.71	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409128305	HYDROMORPHONE HCL (hydromorphone HCl), 0.5 mg/0.5 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	3.14	34.49	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409255201	HYDROMORPHONE HCL (hydromorphone HCl), 1 mg/mL, 10 AMPULS (ML)	Brand	FDA	01/01/2023	2.24	24.61	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409128337	HYDROMORPHONE HCL (hydromorphone HCl), 1 mg/mL, 1X10 NEXTJECT SYRINGES (ML)	Brand	FDA	01/01/2023	4.05	44.57	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409128337	HYDROMORPHONE HCL (hydromorphone HCl), 1 mg/mL, SYRINGE (ML), 10	Brand	FDA	07/01/2023	4.46	49.03	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409263401	HYDROMORPHONE HCL (hydromorphone HCl), 10 mg/mL, VIAL (ML), 1	Generic	FDA	07/01/2023	3.90	42.86	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409131236	HYDROMORPHONE HCL (hydromorphone HCl), 2 mg/mL, 1X10 NEXJECT SYRINGES (ML)	Brand	FDA	01/01/2023	5.43	59.73	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409131230	HYDROMORPHONE HCL (hydromorphone HCl), 2 mg/mL, CARTRIDGE (ML), 1	Brand	FDA	07/01/2023	3.06	33.66	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409131236	HYDROMORPHONE HCL (hydromorphone HCl), 2 mg/mL, SYRINGE (ML), 10	Brand	FDA	07/01/2023	5.97	65.70	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409336510	HYDROMORPHONE HCL (hydromorphone HCl), 2 mg/mL, VIAL (ML), 1	Brand	FDA	07/01/2023	1.74	19.16	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409130431	HYDROMORPHONE HCL (hydromorphone HCl), 4 mg/mL, CARTRIDGE (ML), 1	Brand	FDA	07/01/2023	2.86	31.45	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409255201	Hydromorphone Hydrochloride Injection - Controlled Substance - SCHEDULE II Rx, 1 mg/mL (1 mg/1 mL) Glass Ampul, 10	Brand	FDA	07/01/2023	2.46	27.07	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069018821	IBRANCE (palbociclib), 100 mg, 21 CAPSULES	Brand	FDA	01/01/2023	1103.93	15077.73	03/05/2027	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069048603	IBRANCE (palbociclib), 100 mg, 3X7 BLST TABLETS	Brand	FDA	01/01/2023	1103.93	15077.73	03/05/2027	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069018921	IBRANCE (palbociclib), 125 mg, 21 CAPSULES	Brand	FDA	01/01/2023	1103.93	15077.73	03/05/2027	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069068803	IBRANCE (palbociclib), 125 mg, 3X7 BLST TABLETS	Brand	FDA	01/01/2023	1103.93	15077.73	03/05/2027	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069018721	IBRANCE (palbociclib), 75 mg, 21 CAPSULES	Brand	FDA	01/01/2023	1103.93	15077.73	03/05/2027	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069028403	IBRANCE (palbociclib), 75 mg, 3X7 BLST TABLETS	Brand	FDA	01/01/2023	1103.93	15077.73	03/05/2027	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069014501	INLYTA (axitinib), 1 mg, 180 TABLETS	Brand	FDA	01/01/2023	1404.28	19180.05	04/29/2025	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069014501	INLYTA (axitinib), 1 mg, TABLET, 1	Brand	FDA	07/01/2023	767.20	19947.25	04/29/2025	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069015111	INLYTA (axitinib), 5 mg, 60 TABLETS	Brand	FDA	01/01/2023	1404.28	19180.05	04/29/2025	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069015111	INLYTA (axitinib), 5 mg, TABLET, 1	Brand	FDA	07/01/2023	767.20	19947.25	04/29/2025	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409233934	LABETALOL HCL (labetalol HCI), 20 mg/4 mL (5 mg/mL), CARTRIDGE (ML), 4	Generic	FDA	07/01/2023	8.26	90.83	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069023101	LORBRENA (lorlatinib), 100 mg, 1X30 BTL TABLETS	Brand	FDA	01/01/2023	1475.33	20150.44	03/05/2033	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069022701	LORBRENA (lorlatinib), 25 mg, 1X30 BTL TABLETS	Brand	FDA	01/01/2023	491.77	6716.83	03/05/2033	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409175410	MAGNESIUM SULFATE (magnesium sulfate), 4 mEq/mL (50 %), 10 SYRINGES (ML)	Generic	FDA	01/01/2023	23.00	253.03	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409175410	MAGNESIUM SULFATE (magnesium sulfate), 4 mEq/mL (50 %), SYRINGE (ML), 1	Generic	FDA	07/01/2023	25.30	278.33	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409409101	MANGANESE CHLORIDE (manganese chloride), 0.1 mg/mL, 25 VIALS	Brand	FDA	01/01/2023	63.66	700.21	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409409101	MANGANESE CHLORIDE (manganese chloride), 0.1 mg/mL, VIAL (ML), 25	Brand	FDA	07/01/2023	70.02	770.23	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	70255001002	MEKTOVI (binimetinib), 15 mg, 1X180 BTL TABLETS	Brand	FDA	01/01/2023	1036.58	14157.96	07/04/2031	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	07/30/2019	Array BioPharma Inc.	1120000000	None	On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs.	11499.00	10977.00	2018	10977.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	70255001002	MEKTOVI (binimetinib), 15 mg, TABLET, 180	Brand	FDA	07/01/2023	566.32	14724.28	07/04/2031	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	07/30/2019	Array BioPharma Inc.	1120000000	None	On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs. The acquisition price is $11,200,000,000. The system would not allow us to enter the full acquisition price.	11499.00	10977.00	2018	10977.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409189323	MORPHINE SULFATE (morphine sulfate), 10 mg/mL, 1X10 NEXJECT SYRINGES (ML)	Brand	FDA	01/01/2023	4.20	46.16	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409189301	MORPHINE SULFATE (morphine sulfate), 10 mg/mL, CARTRIDGE (ML), 1	Brand	FDA	07/01/2023	2.10	23.09	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409189323	MORPHINE SULFATE (morphine sulfate), 10 mg/mL, SYRINGE (ML), 10	Brand	FDA	07/01/2023	4.62	50.78	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409189023	MORPHINE SULFATE (morphine sulfate), 2 mg/mL, 1X10 NEXTJECT SYRINGES (ML)	Brand	FDA	01/01/2023	3.54	38.96	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409189023	MORPHINE SULFATE (morphine sulfate), 2 mg/mL, SYRINGE (ML), 10	Brand	FDA	07/01/2023	3.90	42.86	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409189123	MORPHINE SULFATE (morphine sulfate), 4 mg/mL, 1X10 NEXTJECT SYRINGES (ML)	Brand	FDA	01/01/2023	3.57	39.27	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409189123	MORPHINE SULFATE (morphine sulfate), 4 mg/mL, SYRINGE (ML), 10	Brand	FDA	07/01/2023	3.93	43.20	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409189201	MORPHINE SULFATE (morphine sulfate), 8 mg/mL, CARTRIDGE (ML), 1	Brand	FDA	07/01/2023	2.10	23.09	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069131202	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 10 g/100 mL Vial, 1	Brand	FDA	07/01/2023	59.80	2048.20	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069110902	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 2.5 g/25 mL Vial, 1	Brand	FDA	07/01/2023	14.95	512.05	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069141502	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 20 g/200 mL Vial, 1	Brand	FDA	07/01/2023	119.60	4096.40	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069155802	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 30 g/300 mL Vial, 1	Brand	FDA	07/01/2023	178.96	6144.16	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069122402	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 5 g/50 mL Vial, 1	Brand	FDA	07/01/2023	29.90	1024.10	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	60793013110	PENICILLIN G PROCAINE (penicillin G procaine), 1.2 million unit/2 mL, 10 SYRINGES (ML)	Generic	Medispan	01/01/2023	70.23	772.48	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	60793013010	PENICILLIN G PROCAINE (penicillin G procaine), 600,000 unit/mL, 10 SYRINGES (ML)	Generic	Medispan	01/01/2023	41.77	459.51	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409299914	PIPERACILLIN-TAZOBACTAM (piperacillin sodium/tazobactam sodium), 13.5 gram, VIAL (EA), 1	Generic	FDA	07/01/2023	5.43	59.69	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409796905	PLEGISOL (cardioplegic solution no.1), 16 mEq/L (potassium), 12 PLASTIC BAG, PERFUSION (ML)	Brand	FDA	01/01/2023	69.89	768.80	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409796905	PLEGISOL (cardioplegic solution), 1000mL, PLASTIC BAG, PERFUSION (ML), 12	Brand	FDA	07/01/2023	76.88	845.68	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00009335901	PREPIDIL (dinoprostone), 0.5 mg/3 gram, 1X3G PLST GEL WITH PREFILLED APPLICATOR (GRAM)	Brand	FDA	01/01/2023	32.74	687.52	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009335901	PREPIDIL (dinoprostone), 0.5 mg/3 gram, GEL WITH PREFILLED APPLICATOR (GRAM), 1	Brand	FDA	07/01/2023	34.38	721.90	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409553414	SODIUM BICARBONATE (sodium bicarbonate), 0.5 mEq/mL, 1X10 ABBJ SYR SYRINGES (ML)	Generic	FDA	01/01/2023	13.74	151.09	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409491614	SODIUM BICARBONATE (sodium bicarbonate), 0.9 mEq/mL, 1X10 ABBJ SYR SYRINGES (ML)	Generic	FDA	01/01/2023	17.79	195.69	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409663714	SODIUM BICARBONATE (sodium bicarbonate), 1 mEq/mL (8.4 %), 1X10 ABBJ SYR SYRINGES (ML)	Generic	FDA	01/01/2023	13.10	144.11	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409490014	SODIUM BICARBONATE (sodium bicarbonate), 10 mEq/10 mL (8.4 %), 1X10 ABBJ SYR SYRINGES (ML)	Generic	FDA	01/01/2023	17.74	195.13	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409553414	Sodium Bicarbonate Injection Rx, 4.2% (5mEq/10mL) per glass Abboject® syringe, 10	Generic	FDA	07/01/2023	15.11	166.20	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409491614	Sodium Bicarbonate Injection Rx, 7.5% (44/6 mEq/50mL) per glass Abboject® syringe, 10	Generic	FDA	07/01/2023	19.57	215.26	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409490014	Sodium Bicarbonate Injection Rx, 8.4% (10mEq/10mL) per glass vial Abboject® syringe, 10	Generic	FDA	07/01/2023	19.51	214.64	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409663714	Sodium Bicarbonate Injection Rx, 8.4% (50mEq/50mL) per glass Abbotject® syringe, 10	Generic	FDA	07/01/2023	14.41	158.52	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409739172	SODIUM PHOSPHATE (sodium phosphate,monobasic-dibasic), 3 mmol/mL, 25 VIALS	Brand	FDA	01/01/2023	76.15	456.92	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009082501	SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg, VIAL (EA) 1	Brand	FDA	07/01/2023	0.69	14.38	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009001103	SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg/2 mL, VIAL (EA) 1	Brand	FDA	07/01/2023	0.93	19.43	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009001104	SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg/2 mL, VIAL (EA), 1	Brand	FDA	07/01/2023	23.14	485.90	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009001305	SOLU-CORTEF (hydrocortisone sodium succinate), 250 mg/2 mL, VIAL (EA) 1	Brand	FDA	07/01/2023	1.71	35.95	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009001306	SOLU-CORTEF (hydrocortisone sodium succinate), 250 mg/2 mL, VIAL (EA), 1	Brand	FDA	07/01/2023	42.80	898.76	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009001612	SOLU-CORTEF (hydrocortisone sodium succinate), 500 mg/4 mL, VIAL (EA), 1	Brand	FDA	07/01/2023	3.43	71.93	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009000501	SOLU-CORTEF(hydrocortisone sodium succinate), 1000 mg/8 mL, VIAL (EA), 1	Brand	FDA	07/01/2023	6.85	143.83	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409338221	SUFENTANIL CITRATE (sufentanil citrate), 50 mcg/mL, VIAL (ML), 1	Generic	FDA	07/01/2023	6.50	71.48	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069055038	SUTENT (sunitinib malate), 12.5 mg, 28 CAPSULES	Brand	FDA	01/01/2023	298.49	6268.37	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069077038	SUTENT (sunitinib malate), 25 mg, 28 CAPSULES	Brand	FDA	01/01/2023	596.98	12536.76	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069083038	SUTENT (sunitinib malate), 37.5 mg, 28 CAPSULES	Brand	FDA	01/01/2023	895.48	18805.14	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069098038	SUTENT (sunitinib malate), 50 mg, 28 CAPSULES	Brand	FDA	01/01/2023	1039.27	21824.72	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409159304	THAM (tromethamine), 36 mg/mL (0.3 M), INTRAVENOUS SOLUTION, 6	Brand	FDA	07/01/2023	176.97	1946.69	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409159304	THAM (tromethamine), 36 mg/mL (0.3 M), Tham (Tromethamine) Inj Solution 500ml, 1 VIAL	Brand	FDA	01/01/2023	160.88	1769.72	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409357801	TOBRAMYCIN SULFATE (tobramycin sulfate), 40 mg/mL, VIAL (ML), 2	Generic	FDA	07/01/2023	6.78	74.61	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409577901	TPN ELECTROLYTES (multiple electrolyte additive) Solution Rx, 20 mL, 25 VIALS	Brand	FDA	01/01/2023	17.62	193.80	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409577901	TPN ELECTROLYTES (multiple electrolyte additive) Solution Rx, 20 mL, VIAL (ML), 25	Brand	FDA	07/01/2023	19.38	213.18	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00005010010	TRUMENBA (Neisseria meningitidis group B, lipidated fHBP recombinant), 120 mcg/0.5 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	115.51	1789.55	10/01/2026	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00005010005	TRUMENBA (Neisseria meningitidis group B, lipidated fHBP recombinant), 120 mcg/0.5 mL, 5 SYRINGES (ML)	Brand	FDA	01/01/2023	57.75	894.77	10/01/2026	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409963305	VERAPAMIL HCL (verapamil HCl), 2.5 mg/mL, 10 SYRINGES (ML)	Generic	FDA	01/01/2023	61.05	671.53	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409963305	Verapamil Hydrochloride Injection Rx, 2.5 mg/mL (10 mg/4 mL) Ansyr™ Plastic Syringe, 10	Generic	FDA	07/01/2023	67.15	738.68	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	61703030906	VINCRISTINE SULFATE (vincristine sulfate), 1 mg/mL, 1 VIAL	Generic	FDA	01/01/2023	10.30	16.14	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	61703030926	VINCRISTINE SULFATE (vincristine sulfate), 1 mg/mL, 1 VIAL (ML)	Generic	FDA	01/01/2023	8.36	14.11	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	61703030925	VINCRISTINE SULFATE (vincristine sulfate), 2 mg/2 mL, 1 VIAL	Generic	FDA	01/01/2023	4.76	15.45	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	61703030916	VINCRISTINE SULFATE (vincristine sulfate), 2 mg/2 mL, 1 VIAL (ML)	Generic	FDA	01/01/2023	3.16	14.00	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069019730	VIZIMPRO (dacomitinib), 15 mg, 1X30 BTL TABLETS	Brand	FDA	01/01/2023	1139.40	15562.32	08/26/2028	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069119830	VIZIMPRO (dacomitinib), 30 mg, 1X30 BTL TABLETS	Brand	FDA	01/01/2023	1139.40	15562.32	08/26/2028	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069229930	VIZIMPRO (dacomitinib), 45 mg, 1X30 BTL TABLETS	Brand	FDA	01/01/2023	1139.40	15562.32	08/26/2028	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069814120	XALKORI (crizotinib), 200 mg, 60 CAPSULES	Brand	FDA	01/01/2023	1549.10	21157.97	10/08/2029	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069814020	XALKORI (crizotinib), 250 mg, 60 CAPSULES	Brand	FDA	01/01/2023	1549.10	21157.97	10/08/2029	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069100201	XELJANZ (tofacitinib citrate), 10 mg, XELJANZ 10mg FCT 1x60 BTL TABLETS	Brand	FDA	01/01/2023	312.10	5513.77	12/08/2025	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069100101	XELJANZ (tofacitinib citrate), 5 mg, 60 TABLETS	Brand	FDA	01/01/2023	312.10	5513.77	12/08/2025	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069050130	XELJANZ XR (tofacitinib citrate), 11 mg, 1x30 TABLETS	Brand	FDA	01/01/2023	312.10	5513.77	12/08/2025	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069050230	XELJANZ XR (tofacitinib citrate), 22 mg, 1X30 BTL TABLETS	Brand	FDA	01/01/2023	312.10	5513.77	12/08/2025	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409409001	ZINC CHLORIDE (zinc chloride), 1 mg/mL, 25 VIALS	Brand	FDA	01/01/2023	53.84	592.30	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121064610	Amantadine HCl Oral Solution 50 MG/5ML, 10mL, 100ct, oral solution in one unit dose cup	Generic	FDA	12/11/2023	38.50	359.35	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121154410	HYDROcodone-Acetaminophen Oral Solution 2.5-108 MG/5ML, 10mL single count unit dose cup	Generic	FDA	12/11/2023	1.23	9.41	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121477205	HYDROcodone-Acetaminophen Oral Solution 2.5-108 MG/5ML, 5mL single count unit dose cup	Generic	FDA	12/11/2023	1.11	8.45	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121154440	HYDROcodone-Acetaminophen Oral Solution 2.5-108 MG/5ML, 5mL, 40 count unit dose cup	Generic	FDA	12/11/2023	49.08	376.29	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121477240	HYDROcodone-Acetaminophen Oral Solution 2.5-108 MG/5ML, 5mL, 40 count unit dose cups	Generic	FDA	12/11/2023	44.06	337.81	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121202410	Lacosamide Oral Solution 10 MG/ML, 10mL single unit dose cup	Generic	FDA	12/11/2023	9.81	49.03	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121202495	Lacosamide Oral Solution 10 MG/ML, 10mL, 10ct unit dose cups	Generic	FDA	12/11/2023	98.05	490.25	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121303615	Lacosamide Oral Solution 10 MG/ML, 15mL single unit dose cup	Generic	FDA	12/11/2023	14.71	73.54	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121303695	Lacosamide Oral Solution 10 MG/ML, 15mL, 10 count unit dose cups	Generic	FDA	12/11/2023	147.08	735.38	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121404895	Lacosamide Oral Solution 10 MG/ML, 20mL, 10ct unit dose cups	Generic	FDA	12/11/2023	196.10	980.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121404874	Lacosamide Oral Solution 10 MG/ML, 20mL, one single dose cup	Generic	FDA	12/11/2023	19.61	98.05	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121101295	Lacosamide Oral Solution 10 MG/ML, 5mL 10count unit dos cups	Generic	FDA	12/11/2023	49.03	245.13	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121101205	Lacosamide Oral Solution 10 MG/ML, 5mL single unit dos cup	Generic	FDA	12/11/2023	4.90	24.51	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	06/30/2023	00121115400	Lactulose Oral Solution 10 GM/15ML, 100ct 30mL unit dose cups	Generic	FDA	04/01/2023	44.14	112.04	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121457715	Lactulose Oral Solution 10 GM/15ML, 15mL UDC, 15ct	Generic	FDA	12/11/2023	0.38	1.46	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121457740	Lactulose Oral Solution 10 GM/15ML, 15mL Unit dose cups, 100 count	Generic	FDA	12/11/2023	15.12	58.32	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121115430	Lactulose Oral Solution 10 GM/15ML, 30mL single UDC	Generic	FDA	12/11/2023	0.38	1.64	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121115400	Lactulose Oral Solution 10 GM/15ML, 30mL UDC, 100ct	Generic	FDA	12/11/2023	39.21	151.25	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121115440	Lactulose Oral Solution 10 GM/15ML, 30mL UDC, 40ct	Generic	FDA	12/11/2023	15.12	65.52	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	06/30/2023	00121115440	Lactulose Oral Solution 10 GM/15ML, 40ct 30mL unit dose cups, 10 UDCs per tray, 4 trays in one carton	Generic	FDA	04/01/2023	18.90	50.40	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	06/30/2023	00121457740	Lactulose Oral Solution 10 GM/15ML, one single 15mL unit dose cup	Generic	FDA	04/01/2023	16.20	43.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	06/30/2023	00121457715	Lactulose Oral Solution 10 GM/15ML, single 15mL unit dose cup	Generic	FDA	04/01/2023	0.40	1.08	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	06/30/2023	00121115430	Lactulose Oral Solution 10 GM/15ML, single 30mL unit dose cup	Generic	FDA	04/01/2023	0.47	1.26	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	06/30/2023	00121090315	Lidocaine Viscous HCl Mouth/Throat Solution 2 % 15mL, 1 unit dose cup	Generic	FDA	06/01/2023	1.78	3.74	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	06/30/2023	00121090340	Lidocaine Viscous HCl Mouth/Throat Solution 2 % 15mL, 40CT Unit Dose Cups 10 cups in 4 trays.	Generic	FDA	06/01/2023	71.00	149.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	0.00	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121157610	Metoclopramide HCl Oral Solution 10 MG/10ML, 10mL 100ct Unit Dose Cups	Generic	FDA	12/11/2023	52.85	405.21	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121086805	Nystatin Mouth/Throat Suspension 100000 UNIT/ML, 20mL Unit Dose Cup	Generic	FDA	12/11/2023	0.56	1.96	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121086850	Nystatin Mouth/Throat Suspension 100000 UNIT/ML, 20mL, 40ct Unit Dose cups	Generic	FDA	12/11/2023	28.00	98.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121086800	Nystatin Mouth/Throat Suspension 100000 UNIT/ML, 5mL, 100ct Unit Dose Cups	Generic	FDA	12/11/2023	51.00	188.85	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121085320	Sulfamethoxazole-Trimethoprim Oral Suspension 200-40 MG/5ML 20 mL Unit dose cup Oral Suspension	Generic	Medispan	12/11/2023	4.97	14.91	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121085340	Sulfamethoxazole-Trimethoprim Oral Suspension 200-40 MG/5ML 20mL, 40ct Unit Dose Cups, Oral Suspension	Generic	Medispan	12/11/2023	198.84	596.52	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	06/30/2023	00121067585	VALPROIC ACID ORAL SOLN - 16oz Rx 12/cs 250 MG/5ML	Generic	FDA	06/01/2023	6.25	18.75	12/15/2020	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121135010	Valproic Acid Oral Solution 250 MG/5ML, 10mL 1 single unit dose	Generic	FDA	12/11/2023	0.64	2.24	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121135000	Valproic Acid Oral Solution 250 MG/5ML, 10mL, 100ct unit dose cups	Generic	FDA	12/11/2023	64.14	224.48	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121467505	Valproic Acid Oral Solution 250 MG/5ML, 5mL single unit dose cup	Generic	FDA	12/11/2023	0.37	1.25	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121467500	Valproic Acid Oral Solution 250 MG/5ML, 5mL, 100ct unit dose cups	Generic	FDA	12/11/2023	36.90	124.79	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121467540	Valproic Acid Oral Solution 250 MG/5ML, 5mL, 40ct unit dose cups	Generic	FDA	12/11/2023	22.47	78.65	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000319	Pharmacosmos Therapeutics	12/31/2023	73594931001	Monoferric (ferric derisomaltose), Injection 1000mg/10mL 1 unit vial	Brand	FDA	10/01/2023	214.41	3006.27	06/22/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2023	57962014012	Imbruvica 120 Oral Capsule 140 MG	Brand	FDA	01/01/2023	1324.68	22690.52	04/24/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2023	57962007028	Imbruvica 28 Oral Capsule 70 MG	Brand	FDA	01/01/2023	927.28	15883.36	04/24/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2023	57962001428	Imbruvica 28 Oral Tablet 140 MG	Brand	FDA	01/01/2023	927.28	15883.36	03/03/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2023	57962028028	Imbruvica 28 Oral Tablet 280 MG	Brand	FDA	01/01/2023	927.28	15883.36	03/03/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2023	57962042028	Imbruvica 28 Oral Tablet 420 MG	Brand	FDA	01/01/2023	927.28	15883.36	03/03/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2023	57962056028	Imbruvica 28 Oral Tablet 560 MG	Brand	FDA	01/01/2023	927.28	15883.36	03/03/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2023	57962014009	Imbruvica 90 Oral Capsule 140 MG	Brand	FDA	01/01/2023	993.51	17017.89	04/24/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000469	Pharming Healthcare Inc	03/31/2023	71274035002	Ruconest 2100 U; Injection; Powder for Solution; 1 Carton	Brand	FDA	01/13/2023	410.00	7270.00	10/07/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000536	Protega Pharmaceuticals, Inc.	03/29/2024	81140010210	RoxyBond Oral Tablet Abuse-Deterrent 15 MG sold to pharmacists in bottles of 100 tablets	Brand	FDA	04/01/2023	141.46	1570.30	08/12/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000536	Protega Pharmaceuticals, Inc.	03/29/2024	81140010310	RoxyBond Oral Tablet Abuse-Deterrent 30 MG sold to pharmacists in bottles of 100 tablets	Brand	FDA	04/01/2023	190.64	2116.28	08/12/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000536	Protega Pharmaceuticals, Inc.	03/29/2024	81140010110	RoxyBond Oral Tablet Abuse-Deterrent 5 MG sold to pharmacists in bottles of 100 tablets	Brand	FDA	04/01/2023	114.70	1273.28	08/12/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000236	PTC Therapeutics, Inc	03/31/2023	52856050203	EMFLAZA (deflazacort) 18mg tabs/30 ct	Brand	FDA	01/16/2023	664.94	7738.67	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	3925.00	0.00	2017	3925.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	06/30/2023	52856050203	EMFLAZA (deflazacort) 18mg tabs/30 ct	Brand	FDA	05/01/2023	1470.34	9209.01	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	3925.00	0.00	2017	3925.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	03/31/2023	52856050522	EMFLAZA (deflazacort) 22.75 mg/ml susp/13 mL in 1 BOTTLE	Brand	FDA	01/16/2023	486.72	5664.51	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	2873.00	0.00	2017	2873.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	06/30/2023	52856050522	EMFLAZA (deflazacort) 22.75 mg/ml susp/13 mL in 1 BOTTLE	Brand	FDA	05/01/2023	1076.25	6740.76	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	2873.00	0.00	2017	2873.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	03/31/2023	52856050303	EMFLAZA (deflazacort) 30mg tabs/30 ct	Brand	FDA	01/16/2023	1108.27	12898.43	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	6542.00	0.00	2017	6542.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	06/30/2023	52856050303	EMFLAZA (deflazacort) 30mg tabs/30 ct	Brand	FDA	05/01/2023	2450.71	15349.14	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	6542.00	0.00	2017	6542.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	03/31/2023	52856050403	EMFLAZA (deflazacort) 36mg tabs/30 ct	Brand	FDA	01/16/2023	1282.95	14931.40	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	7290.00	0.00	2017	7290.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	06/30/2023	52856050403	EMFLAZA (deflazacort) 36mg tabs/30 ct	Brand	FDA	05/01/2023	2836.96	17768.36	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	7290.00	0.00	2017	7290.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	03/31/2023	52856050101	EMFLAZA (deflazacort) 6mg tabs/100 ct	Brand	FDA	01/16/2023	738.80	8598.30	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	4361.00	0.00	2017	4361.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	06/30/2023	52856050101	EMFLAZA (deflazacort) 6mg tabs/100 ct	Brand	FDA	05/01/2023	1633.68	10231.98	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	4361.00	0.00	2017	4361.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000220	Puma Biotechnology, Inc.	03/31/2023	70437024033	Nerlynx Oral Tablet 40 mg, 133 tablet package	Brand	FDA	01/13/2023	1055.00	15295.00	07/18/2031	Single Source Drug	619	None	Inflation has driven up costs in almost all areas of operations.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000220	Puma Biotechnology, Inc.	03/31/2023	70437024018	Nerlynx Oral Tablet 40 mg, 180 tablet package	Brand	FDA	01/13/2023	1425.00	20700.00	07/18/2031	Single Source Drug	11943	None	Inflation has driven up costs in almost all areas of operations.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None